+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of FLT3-ITD Positive Acute Myelogenous Leukemia with Allogeneic and Autologous Stem Cell Transplantation - Results in 175 Patients

Treatment of FLT3-ITD Positive Acute Myelogenous Leukemia with Allogeneic and Autologous Stem Cell Transplantation - Results in 175 Patients

Blood 100(11): Abstract No 2957, November 16

Activating mutations of the FLT3 receptor tyrosine kinase, either by internal tandem duplication (ITD) mutations of the juxtamembrane domain or point mutations of the tyrosine kinase domain, are common alterations in adult AML. Several groups have shown that FLT3-ITD mutations are associated with inferior outcome after standard chemotherapy. The adequate treatment for these patients is still unclear. Autologous and allogeneic stem cell transplantation (SCT) are curative treatment options for patients with AML and are offered especially to patients with intermediate and high risk cytogenetics. In the current analysis we asked for the outcome of AML patients with FLT3-ITD mutations treated with SCT. Methods: 329 adult patients with de novo AML and intermediate risk cytogenetics, i.e. normal karyotype (n=234) and other non high risk or good risk cytogenetics (n=84), (unknown n =11) age 60 and younger treated in the AML96 multicenter protocol of the Sueddeutsche Haemoblastose Group were analyzed retrospectively. Of these patients 92 were treated by autologous and 83 by allogeneic (matched sibling donor: n= 66; matched unrelated donor: n=17) SCT. Analysis for FLT3-ITD mutations was performed by PCR using genomic DNA obtained at diagnosis. In addition, quantitative analysis for the mutant to wt ratio was done in FLT3-ITD pos. cases. Results: FLT3-ITD mutations were found in 85/329 cases (25.8%). Overall, the presence of a FLT3-ITD mutation was associated with an inferior outcome (median overall survival (OS) FLT3-ITD pos. vs. neg.: 14.7 vs. 26.5; p= .0961; median disease free survival (DFS): 11.6 vs. 28.9 p=0.05). When the different treatment arms were analyzed separately, no difference in OS and DFS was found in patients treated by autologous and unrelated allogeneic SCT. In patients with related donor an unsuspected difference was observed, due to an increased rate of relapse: 52.9% vs. 14.9% (p= .0017). The most prominent survival difference was found in patients treated with chemotherapy only (OS FLT-ITD pos. vs. neg.: 5 vs. 9.6 months; p= .009; DFS: 4 vs. 17 months, p= .02) due to a highly increased early relapse rate. This finding was most evident in patients with a high/mutant to wt ratio, indicating loss of the wt-FLT3 allele. Conclusions: In patients treated with autologous transplantation, FLT3-ITD mutations are not associated with an inferior outcome. The role of allogeneic transplantation remains to be defined, but relapse is a major cause of treatment failure in FLT3-ITD+ patients

(PDF emailed within 1 workday: $29.90)

Accession: 035980409

Download citation: RISBibTeXText

Related references

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation. Biology of Blood and Marrow Transplantation 22(6): 982-990, 2016

Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 97(7): 1721-1731, 2003

Comparison of Allogeneic Stem Cell Transplantation , High-Dose Cytarabine , and Autologous Peripheral Blood Stem Cell Transplantation as Post-Remission Treatment in Patients with De Novo Acute Myelogenous Leukemia. Blood 100(11): Abstract No 3395, November 16, 2002

Treatment of FLT3-ITD Positive Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation with Sorafenib. 2011

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biology of Blood and Marrow Transplantation 17(12): 1874-1877, 2012

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation 22(7): 1218-1226, 2016

Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Journal of Cancer Research and Clinical Oncology (): -, 2016

The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Zhonghua Nei Ke Za Zhi 55(8): 634-636, 2016

Treatment of therapy - induced myelodysplastic syndrome /acute myelogenous leukemia with high-dose chemo/radiotherapy and autologous or allogeneic stem cell transplantation. Clinical & Investigative Medicine (SUPPL ): S46, 1998

Treatment of childhood acute myelogenous leukemia with allogeneic and autologous stem cell transplantation during the first remission: A report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan. Pediatric Hematology & Oncology 17(8): 623-634, December, 2000

Long-term leukemia-free survival of patients with acute myelogenous leukemia after allogeneic stem cell transplantation Report of the Austrian Stem Cell Transplantation Registry. Onkologie 23(Sonderheft 7): 1, October, 2000

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 113(26): 6567-6571, 2009

Daunorubicin vs mitoxantrone vs idarubicin administered during induction and consolidation in acute myelogenous leukemia followed by autologous or allogeneic stem transplantation Results of the EORTC-GIMEMA. Blood 102(11): 175a, November 16, 2003

Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 90(10): 1346-1356, 2005